Premium
Risk factors associated with the need for additional intravenous gamma‐globulin therapy for Kawasaki disease
Author(s) -
Muta Hiromi,
Ishii Masahiro,
Furui Jun,
Nakamura Yosikazu,
Matsuishi Toyojiro
Publication year - 2006
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2006.tb02205.x
Subject(s) - medicine , odds ratio , kawasaki disease , gamma globulin , logistic regression , cervical lymphadenopathy , gastroenterology , disease , risk factor , confidence interval , surgery , immunology , artery , antibody
Aim: To investigate the characteristics of patients with Kawasaki disease who needed intravenous gamma‐globulin (IVGG) re‐treatment. Methods: Using the database of the 17th nationwide survey in Japan, a total 11 366 patients were identified and analysed (1855 re‐treatment patients and 9511 responders). Results: Multivariate logistic regression analysis showed that male sex (odds ratio (OR) 1.26; 95% CI 1.14–1.40), complete cases (OR 1.39; 95% CI 1.07–1.80), recurrence (OR 1.47; 95% CI 1.15–1.88), IVGG treatment within 4 d of illness (OR 2.05; 95% CI 1.84–2.27), daily dose of initial IVGG less than 1000 mg/Kg (OR 0.54; 95% CI 0.48–0.61), exanthema (OR 2.03; 95% CI 1.62–2.56), lips and oral lesions (OR 1.57; 95% CI 1.24–1.98), peripheral extremities changes (OR 1.85; 95% CI 1.54–2.22), and cervical lymphadenopathy (OR 1.89; 95% CI 1.66–2.16) were independent risk factors associated with the need for IVGG re‐treatment. Conclusion: Male sex, recurrence, and treatment with IVGG at a dose of 1000 mg/d or less within 4 d of illness onset are independent risk factors associated with the need for IVGG re‐treatment.